Recombinant SARS-CoV-2 3CL Protease (rSARS-CoV-23CLProtease)
The 3CL protease (aka 3CLpro, Mpro or “Main” Protease) from the human SARS-CoV-2 coronavirus (Severe Acute Respiratory Syndrome coronavirus 2) is a C30-type cysteine protease. 3CLpro activity is required to process the viral polyprotein into functional, mature subunits, and there are 11 or more sites of cleavage, many containing the sequence LQ[S/A/G]; the protease cleaves c-terminal to the glutamine amino acid. Along with the CoV-2 Papain-Like Protease, 3CLpro presents an attractive target for therapeutic intervention for COVID-19. Because no human proteases with a similar cleavage specificity are known, inhibitors of 3CLpro are unlikely to cause mechanism-based toxicity.
Test in process.
White lyophilized (freeze-dried) powder.
Lyophilized from a 0.2 um filtered concentrated solution in PBS, pH 7.0, with 5 % Trehalose, 0.02 % Tween-20.
Less than 0.1 EU/ug of rSARS-CoV-2 3CL Protease as determined by LAL method.
We recommend that this vial is briefly centrifuged prior to opening. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 °C as supplied.- 1 month, 2 to 8 °C under sterile conditions after reconstitution.- 3 months, -20 to -70 °C under sterile conditions after reconstitution.
> 97 % by SDS-PAGE.
Recombinant SARS-CoV-2 3CL Protease是ChemWhat品牌授权产品并通过沃尔森销售，下面是ChemWhat上的该产品链接 Recombinant SARS-CoV-2 3CL Protease (rSARS-CoV-23CLProtease)